We demonstrate that RDX8940, a potent, selective, minimally systemic oral TGR5 agonist, improves liver steatosis and insulin sensitivity in a mouse model of NAFLD and does not inhibit gallbladder emptying in mice. Here, GPBAR1 is linked to metabolic dysfunction-associated steatotic liver disease.